Precision oncology is based on a deep understanding of the molecular characteristics of tumors. For this reason, next-generation sequencing (NGS) has become a key tool for selecting targeted and biomarker-driven therapies.
According to data from a large-scale clinical study published in Nature, a significant proportion of patients with solid tumors harbor clinically relevant genomic alterations. The use of NGS-based Comprehensive Genomic Profiling (CGP) enables the detection of these alterations and improves treatment effectiveness in real-world clinical practice. These findings confirm that timely and comprehensive molecular diagnostics form the foundation of modern cancer detection and management.
One of the clinical solutions available is the TRUNGS® Solid Tumour Panel — a targeted NGS panel designed for the simultaneous detection of SNVs, indels, CNVs, and RNA fusions within a single assay. The panel covers 35 clinically relevant genes with a focus on lung cancer and colorectal cancer and complies with international NCCN and ESMO guidelines. High analytical sensitivity and hybrid capture technology ensure reliable results even when working with challenging samples.
An additional advantage is the integration of pharmacogenomic markers, enabling not only the selection of effective therapy but also the reduction of drug-related toxicity risks.
Compatibility with Illumina and MGI platforms makes this solution suitable for implementation in laboratories of various levels.
TRUPCR manufactures NGS kits and software solutions for the interpretation of sequencing results:
-
truNGS® BRCA Plus Kit — designed for the detection of germline and somatic mutations in BRCA1, BRCA2, and other clinically relevant genes associated with hereditary breast and ovarian cancer predisposition.
-
truNGS® Endometrial Cancer Panel Kit — designed to detect clinically significant somatic mutations in genes associated with the development of endometrial cancer.
-
truNGS® Pan-Myeloid Panel Kit — designed to detect somatic mutations in genes associated with myeloid neoplasms.
This material was prepared by Medical Company “Empirica” based on information provided by the manufacturer TRUPCR.
About TRUPCR
TRUPCR is a UK-based manufacturer of molecular diagnostics solutions for qPCR and NGS, founded by a team with over 25 years of experience in laboratory diagnostics and healthcare. The company combines in-depth knowledge of methodologies and laboratory instrumentation to deliver high-quality products, technical support, and training aimed at improving laboratory efficiency.
Medical Company “Empirica” is the official distributor of TRUPCR in Ukraine and provides advanced qPCR and NGS diagnostic solutions for laboratories of various profiles — from clinical diagnostic and oncology laboratories to specialized molecular centers.
Through an expert-driven approach, comprehensive technical support, and a deep understanding of the Ukrainian market, Medical Company “Empirica” helps laboratories implement effective, reliable, and clinically validated molecular diagnostic solutions.
Learn more about NGS diagnostic opportunities for your laboratory together with Medical Company “Empirica”:
📞 +38 (067) 880 44 83
✉️ molbio@empirica.healthcare
